Supernus (SUPN) | Financial Analysis & Statements
Supernus Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
211.6M
Gross Profit
188.6M
89.13%
Operating Income
13.8M
6.53%
Net Income
-4.1M
-1.94%
EPS (Diluted)
$-0.07
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
390.9M
Shareholders Equity
1.1B
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
48.5M
Free Cash Flow
19.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Supernus Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 719.0M | 661.8M | 607.5M | 667.2M | 579.8M |
| Cost of Goods Sold | 74.6M | 77.9M | 83.8M | 87.2M | 75.1M |
| Gross Profit | 644.4M | 583.9M | 523.7M | 580.0M | 504.7M |
| Gross Margin % | 89.6% | 88.2% | 86.2% | 86.9% | 87.1% |
| Operating Expenses | |||||
| Research & Development | 106.2M | 108.8M | 91.6M | 74.6M | 90.5M |
| Selling, General & Administrative | 485.6M | 321.6M | 336.4M | 377.2M | 304.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 591.8M | 430.4M | 428.0M | 451.8M | 395.2M |
| Operating Income | -36.9M | 75.6M | 13.4M | 45.6M | 79.5M |
| Operating Margin % | -5.1% | 11.4% | 2.2% | 6.8% | 13.7% |
| Non-Operating Items | |||||
| Interest Income | 13.3M | 16.2M | 10.5M | 21.7M | 10.6M |
| Interest Expense | 0 | 0 | 2.4M | 7.1M | 23.4M |
| Other Non-Operating Income | -25.4M | 6.1M | -18.7M | 510.0K | 6.5M |
| Pre-tax Income | -49.0M | 97.9M | 2.8M | 60.7M | 73.2M |
| Income Tax | -10.5M | 24.0M | 1.5M | 32.0K | 19.8M |
| Effective Tax Rate % | 0.0% | 24.5% | 52.5% | 0.1% | 27.0% |
| Net Income | -38.6M | 73.9M | 1.3M | 60.7M | 53.4M |
| Net Margin % | -5.4% | 11.2% | 0.2% | 9.1% | 9.2% |
| Key Metrics | |||||
| EBITDA | 68.0M | 172.2M | 108.7M | 152.8M | 122.7M |
| EPS (Basic) | $-0.68 | $1.34 | $0.02 | $1.13 | $1.01 |
| EPS (Diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 |
| Basic Shares Outstanding | 56451136 | 55100063 | 54536281 | 53665143 | 53099330 |
| Diluted Shares Outstanding | 56451136 | 55100063 | 54536281 | 53665143 | 53099330 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Supernus Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 128.4M | 69.3M | 75.1M | 93.1M | 203.4M |
| Short-term Investments | 180.2M | 384.3M | 179.8M | 368.2M | 136.2M |
| Accounts Receivable | 187.8M | 142.1M | 144.2M | 165.5M | 148.9M |
| Inventory | 82.4M | 54.3M | 77.4M | 91.5M | 86.0M |
| Other Current Assets | 65.3M | 36.1M | 16.7M | 15.8M | 27.0M |
| Total Current Assets | 644.2M | 686.1M | 493.1M | 734.2M | 601.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 12.1M | 12.3M |
| Goodwill | 819.2M | 756.0M | 833.9M | 936.5M | 1.0B |
| Intangible Assets | 569.5M | 521.9M | 599.9M | 702.5M | 784.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 103.6M | 31.5M | 37.5M | 39.8M | 49.2M |
| Total Non-Current Assets | 808.5M | 682.0M | 784.6M | 968.4M | 1.1B |
| Total Assets | 1.5B | 1.4B | 1.3B | 1.7B | 1.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 2.7M | 4.6M | 2.0M | 10.5M | 9.3M |
| Short-term Debt | 10.6M | 6.9M | 8.3M | 408.8M | 6.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 69.3M | 47.3M | 56.4M | 38.0M | 65.0M |
| Total Current Liabilities | 338.2M | 292.4M | 290.2M | 688.0M | 315.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 30.4M | 27.4M | 33.2M | 36.0M | 420.6M |
| Deferred Tax Liabilities | 0 | 5.0M | 25.0M | 49.8M | 85.4M |
| Other Non-Current Liabilities | 22.4M | 7.6M | 7.8M | 42.5M | 52.0M |
| Total Non-Current Liabilities | 52.8M | 39.9M | 66.0M | 128.3M | 557.9M |
| Total Liabilities | 390.9M | 332.3M | 356.2M | 816.3M | 873.3M |
| Equity | |||||
| Common Stock | 57.0K | 56.0K | 55.0K | 54.0K | 53.0K |
| Retained Earnings | 517.9M | 556.4M | 482.6M | 481.2M | 379.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.1B | 1.0B | 921.5M | 886.2M | 815.9M |
| Key Metrics | |||||
| Total Debt | 41.0M | 34.3M | 41.5M | 444.8M | 427.0M |
| Working Capital | 306.0M | 393.7M | 202.9M | 46.2M | 286.2M |
Balance Sheet Composition
Supernus Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -38.6M | 73.9M | 1.3M | 60.7M | 53.4M |
| Depreciation & Amortization | 91.6M | 80.4M | 84.9M | 85.5M | 32.6M |
| Stock-Based Compensation | 33.1M | 27.8M | 26.8M | 17.6M | 17.9M |
| Working Capital Changes | -54.4M | 2.9M | -11.4M | -55.5M | 7.5M |
| Operating Cash Flow | 67.3M | 166.2M | 88.7M | 82.4M | 131.0M |
| Investing Activities | |||||
| Capital Expenditures | -1.3M | -725.0K | -551.0K | -412.0K | -2.0M |
| Acquisitions | -293.1M | - | 0 | 0 | -311.7M |
| Investment Purchases | -475.9M | -688.0M | -101.6M | -407.0M | -311.6M |
| Investment Sales | 774.5M | 498.9M | 370.9M | 190.7M | 530.5M |
| Investing Cash Flow | 4.1M | -189.9M | 268.7M | -216.7M | -94.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 0 | 0 | 0 | 800.0K |
| Debt Repayment | 0 | 0 | -495.5M | 0 | -138.3M |
| Financing Cash Flow | 9.1M | 12.2M | -893.4M | -10.5M | -130.4M |
| Free Cash Flow | 46.0M | 171.2M | 110.5M | 116.4M | 125.1M |
| Net Change in Cash | 80.5M | -11.5M | -535.9M | -144.8M | -94.3M |
Cash Flow Trend
Supernus Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
40.66
Forward P/E
11.64
Price to Book
2.66
Price to Sales
3.93
PEG Ratio
-0.33
Profitability Ratios
Profit Margin
-5.36%
Operating Margin
5.57%
Return on Equity
-3.68%
Return on Assets
1.14%
Financial Health
Current Ratio
1.90
Debt to Equity
3.86
Beta
0.73
Per Share Data
EPS (TTM)
$-0.68
Book Value per Share
$18.48
Revenue per Share
$12.74
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SUPN | 2.8B | 40.66 | 2.66 | -3.68% | -5.36% | 3.86 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Alkermes plc | 5.6B | 23.71 | 3.09 | 14.72% | 16.37% | 3.85 |
| Lantheus Holdings | 5.4B | 24.30 | 4.91 | 21.45% | 15.15% | 57.19 |
| Amneal | 4.2B | 63.23 | -57.42 | -101.02% | 2.39% | 45,095.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






